Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.
You may also be interested in...
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.
CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December
Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.
Minute Insight: Activ Surgical Wins CE Mark For ActivSight
After winning US FDA clearance in 2021, Activ Surgical now also received the green light to market its visualization module for surgeons in Europe.